Tag: Frost & Sullivan
China’s YishengBio eyes US capital markets via SPAC route
Yisheng Biopharma has abandoned its Hong Kong IPO and turned instead to the Nasdaq via the SPAC route in a deal that is expected to be sealed by the first quarter of 2023
HKEX gong chimes as GoGoX goes public
China’s third largest online logistics platform has debuted on the Hong Kong bourse – a move that summoned the strike of the gong back to the trading floor
Diagnostic provider Yunkang goes public in HK
The fifth-largest market player in China’s medical operation services sector has been listed on the HKEX
LATEST ON VANTAGE ASIA
MOST READ ON VANTAGE ASIA
Roadmap for a superhighway
How can India plug the legal and regulatory gaps that are holding back the nation’s massive infrastructure sector?
2024: Spheres of influence
A slowing China, the rise in AI and global geopolitics all make for an interesting 2024 for Asia’s legal markets
